Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Takashi, Takata, Kazuhide, Yokoyama, Keiji, Fukuda, Hiromi, Yamauchi, Ryo, Fukunaga, Atsushi, Shakado, Satoshi, Sakisaka, Shotaro, Hirai, Fumihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/
https://www.ncbi.nlm.nih.gov/pubmed/35877241
http://dx.doi.org/10.3390/curroncol29070381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/
https://www.ncbi.nlm.nih.gov/pubmed/35877241
http://dx.doi.org/10.3390/curroncol29070381

Ejemplares similares